Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
|Articles|February 14, 2019
THE REALITY OF CONTINUOUS PHARMACEUTICAL MANUFACTURING
Author(s)GEA Group
Advertisement
User experiences and the current status of continuous pharmaceutical processing to be addressed during a three-day event near Newcastle, UK
Taking place on 26–28 March 2019, GEA, Siemens and Perceptive Engineering will host an inaugural 3-day conference to examine the fact and fiction of Continuous Manufacturing (CM) in the pharmaceutical industry.
Hear from experts across the industry including AstraZeneca, Bayer, CMAC, GSK, Janssen, MSD, RCPE, UCB Pharma and University of Sheffield to name a few.
With an expected attendance of 80–120 delegates, this must-attend event will focus on the real-life experiences of existing users of CM technology in the development and manufacture of oral solid dosage (OSD) forms.
Contact Details:
Company name: GEA Group
Website:
E-mail: [email protected]
Advertisement
Related to this article
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Advertisement
Advertisement